The first ever clinical trial of a therapeutic antibody that binds to natural killer (NK) cell receptors is slated to take place before the year end.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Related links
Related links
Related links in Nature Research
Toll-like receptor therapies compete to reduce side effects
Web links
Rights and permissions
About this article
Cite this article
Sheridan, C. First in class stimulates natural killer cells. Nat Biotechnol 24, 597 (2006). https://doi.org/10.1038/nbt0606-597
Published:
Issue date:
DOI: https://doi.org/10.1038/nbt0606-597
This article is cited by
-
Natural killer cells and malignant haemopathies: a model for the interaction of cancer with innate immunity
Cancer Immunology, Immunotherapy (2011)
-
Natural killer cell–directed therapies: moving from unexpected results to successful strategies
Nature Immunology (2008)
-
NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy
Cancer Immunology, Immunotherapy (2008)
-
Prospects for the use of NK cells in immunotherapy of human cancer
Nature Reviews Immunology (2007)
